Professional
Added to YB: 2025-05-05
Pitch date: 2025-05-01
AKBLF [neutral]
ALK-Abelló A/S
+44.61%
current return
Author Info
Mr. Market Miscalculates (mostly) shares overlooked or misunderstood small/mid-cap European companies. Sign up for the newsletter.
Company Info
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
Market Cap
DKK 33.6B
Pitch Price
DKK 154.90
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.71
P/E
41.30
EV/Sales
6.18
Sector
Pharmaceuticals
Category
growth
Monthly Recap - ALK-Abelló A/S
AKBLF (quick overview): Leading Allergy Immunotherapy firm up 15% revenue, 65% profits, expanding margins in 2024. Projecting 9-13% growth, 25% EBIT margin (+5%) for 2025. Stock +19% since initial report, now at P/E 40x, EV/EBIT 30x, FCF yield ~2%. Quality company, potential takeover target.
Read full article (1 min)